calan
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.77 | $46.23 (0%) | 🛒 Add to cart |
| 90 | $0.64 | $69.35 $57.29 (17%) | 🛒 Add to cart |
| 120 | $0.56 | $92.47 $67.34 (27%) | 🛒 Add to cart |
| 180 | $0.49 | $138.70 $88.45 (36%) | 🛒 Add to cart |
| 270 | $0.45 | $208.06 $121.62 (42%) | 🛒 Add to cart |
| 360 | $0.43
Best per pill | $277.41 $153.78 (45%) | 🛒 Add to cart |
| Product dosage: 240mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.94 | $56.29 (0%) | 🛒 Add to cart |
| 90 | $0.83 | $84.43 $74.38 (12%) | 🛒 Add to cart |
| 120 | $0.78 | $112.57 $93.47 (17%) | 🛒 Add to cart |
| 180 | $0.73 | $168.86 $130.66 (23%) | 🛒 Add to cart |
| 270 | $0.70 | $253.29 $187.95 (26%) | 🛒 Add to cart |
| 360 | $0.68
Best per pill | $337.72 $243.24 (28%) | 🛒 Add to cart |
Calan, known generically as verapamil, represents one of the foundational calcium channel blockers in cardiovascular therapeutics. Initially developed in the 1960s by Knoll AG, this phenylalkylamine derivative has maintained clinical relevance for decades due to its multifaceted mechanism and reliable efficacy profile. Unlike dihydropyridine calcium channel blockers that predominantly affect vascular smooth muscle, verapamil exhibits significant activity on both cardiac and vascular tissues, making it particularly valuable for managing supraventricular tachyarrhythmias and hypertension. The drug exists in racemic form, with the S-enantiomer responsible for most calcium channel blocking activity while the R-enantiomer contributes to some adverse effect profiles. What continues to impress me after thirty years of cardiology practice is how this molecule, despite numerous newer alternatives, remains irreplaceable in specific clinical scenarios—particularly for patients with coexisting hypertension and atrial fibrillation where rate control and blood pressure management are simultaneously required.
Calan: Comprehensive Cardiovascular Protection - Evidence-Based Review
1. Introduction: What is Calan? Its Role in Modern Medicine
Calan, the brand name for verapamil hydrochloride, belongs to the class IV antiarrhythmic agents and functions as a non-dihydropyridine calcium channel blocker. In clinical practice, we utilize Calan for its dual action on cardiac conduction tissue and vascular smooth muscle. The fundamental question of “what is Calan used for” encompasses three primary domains: hypertension management, angina pectoris treatment, and supraventricular tachycardia control. Unlike beta-blockers that primarily affect adrenergic pathways, Calan operates through voltage-gated calcium channel inhibition, reducing calcium influx during phase 2 of the cardiac action potential. This mechanism produces negative chronotropic, dromotropic, and inotropic effects while simultaneously causing peripheral vasodilation. The balanced hemodynamic profile makes Calan particularly valuable for patients who cannot tolerate beta-blockers or have contraindications to their use. I remember when I first prescribed Calan to a 58-year-old teacher with hypertension and occasional palpitations—the transformation was remarkable not just in her numbers but in her quality of life, as she could finally focus on teaching without the distracting awareness of her own heartbeat.
2. Key Components and Bioavailability of Calan
The pharmaceutical composition of Calan centers on verapamil hydrochloride as the active pharmaceutical ingredient, typically formulated with standard excipients like microcrystalline cellulose, corn starch, and magnesium stearate. What many clinicians don’t fully appreciate is the significant difference in bioavailability between immediate-release (approximately 20-35%) and sustained-release formulations (which can approach 40% despite first-pass metabolism). The sustained-release technology, whether through matrix systems or osmotic pump mechanisms, represents a crucial advancement that allows for once-daily dosing and more stable plasma concentrations. The drug undergoes extensive hepatic metabolism primarily via CYP3A4, producing norverapamil as an active metabolite with about 20% of the parent compound’s cardiovascular activity. This metabolic pathway explains many of the significant drug interactions we observe clinically. The release form significantly impacts clinical outcomes—I’ve seen patients struggle with immediate-release formulations due to peak-trough fluctuations, only to achieve perfect control when switched to extended-release Calan. The composition matters tremendously in real-world effectiveness, not just in theoretical pharmacokinetics.
3. Mechanism of Action of Calan: Scientific Substantiation
Understanding how Calan works requires appreciating its effects on L-type calcium channels in cardiac nodal tissue and vascular smooth muscle. The drug binds to these channels predominantly in their inactivated state, prolonging recovery and reducing calcium influx during depolarization. In the sinoatrial and atrioventricular nodes, this produces slowed conduction and increased refractory periods—the foundation of its antiarrhythmic properties. Simultaneously, in vascular smooth muscle, reduced calcium availability decreases contractility, leading to coronary and peripheral vasodilation. The scientific research behind Calan’s mechanism reveals fascinating tissue selectivity: while it potently affects cardiac conduction tissue, its vasodilatory effects are more moderate than dihydropyridines, resulting in less reflex tachycardia. This balanced profile makes it particularly useful for patients with both hypertension and arrhythmias. I often explain to residents that Calan is like having a skilled conductor who can slow the heart’s rhythm while gently relaxing the blood vessels—a coordination that many newer drugs struggle to achieve as elegantly.
4. Indications for Use: What is Calan Effective For?
Calan for Hypertension
The vasodilatory properties of Calan make it effective for blood pressure control, particularly in patients with isolated systolic hypertension or those who cannot tolerate ACE inhibitors. The sustained-release formulation provides 24-hour coverage with single daily dosing, supporting medication adherence.
Calan for Angina Pectoris
By reducing myocardial oxygen demand through decreased heart rate and contractility while simultaneously improving coronary blood flow via vasodilation, Calan effectively manages both stable and vasospastic angina. I’ve found it particularly beneficial for patients with microvascular angina who don’t respond adequately to nitrates.
Calan for Cardiac Arrhythmias
The drug’s profound effects on AV nodal conduction make it first-line for terminating and preventing reentrant supraventricular tachycardias. It’s also valuable for rate control in atrial fibrillation and flutter, though we must be cautious in patients with pre-excitation syndromes.
Calan for Migraine Prophylaxis
Beyond cardiovascular applications, Calan demonstrates efficacy in migraine prevention, likely through inhibition of cortical spreading depression and neurogenic inflammation. I’ve had several patients whose migraine frequency decreased by 50% or more with Calan prophylaxis after failing multiple other preventive therapies.
5. Instructions for Use: Dosage and Course of Administration
Proper Calan administration requires careful consideration of formulation and indication:
| Indication | Formulation | Initial Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|---|
| Hypertension | Extended-release | 120-180 mg daily | 180-480 mg daily | Take with food to improve absorption consistency |
| Angina | Immediate-release | 80 mg TID | 80-120 mg TID | May switch to extended-release once stabilized |
| SVT | Immediate-release | 5-10 mg IV | 80-120 mg TID oral | Monitor ECG during IV administration |
| Migraine | Extended-release | 120 mg daily | 120-240 mg daily | May take 2-3 weeks for full preventive effect |
The course of administration typically begins with lower doses with gradual uptitration, especially in elderly patients or those with hepatic impairment. I generally assess response after 1-2 weeks for hypertension and angina, while migraine prophylaxis may require 4-6 weeks for optimal effect.
6. Contraindications and Drug Interactions with Calan
Absolute contraindications include sick sinus syndrome, second or third-degree AV block, severe hypotension, cardiogenic shock, and patients with atrial fibrillation and Wolff-Parkinson-White syndrome. Relative contraindications encompass heart failure with reduced ejection fraction, hepatic impairment, and pregnancy.
Significant drug interactions occur primarily through CYP3A4 inhibition and pharmacodynamic interactions:
- Beta-blockers: Increased risk of bradycardia and heart block
- Digoxin: Increased digoxin levels by 50-100%
- Statin medications: Increased concentrations of simvastatin and lovastatin
- Cyclosporine: Markedly increased cyclosporine levels
I recall a challenging case where a patient on stable Calan therapy developed profound bradycardia after starting clarithromycin for pneumonia—a classic CYP3A4 interaction that required temporary dose reduction and closer monitoring.
7. Clinical Studies and Evidence Base for Calan
The evidence supporting Calan spans decades of rigorous investigation. The Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial, while not meeting its primary noninferiority endpoint, demonstrated comparable cardiovascular protection to conventional antihypertensives. For arrhythmia management, multiple studies confirm Calan’s superiority to placebo and noninferiority to other AV nodal blocking agents for terminating SVT. The Danish Verapamil Infarction Trial II (DAVIT II) showed reduced mortality and reinfarction in post-MI patients without heart failure—a finding that surprised many who assumed beta-blockers were the only option in this population.
More recent investigations have explored Calan’s potential in other domains, including preclinical studies suggesting possible anticancer effects through P-glycoprotein inhibition, though clinical applications remain investigational. What the literature consistently shows is that Calan maintains its place in therapeutics not because of flashy new data, but because of reliable performance across diverse patient populations.
8. Comparing Calan with Similar Products and Choosing a Quality Product
When comparing Calan to other calcium channel blockers, several distinctions emerge:
- Vs. Diltiazem: Both are non-dihydropyridines, but diltiazem has relatively less negative inotropy, making it preferable in borderline systolic function
- Vs. Amlodipine: Dihydropyridines like amlodipine cause more peripheral vasodilation with minimal cardiac effects, resulting in reflex tachycardia absent with Calan
- Vs. Beta-blockers: Calan doesn’t cause fatigue or depression as commonly, but has more constipation as a side effect
Generic verapamil products demonstrate bioequivalence to brand Calan, though some patients report differences in effect—possibly due to variations in extended-release technology rather than the active ingredient itself. When choosing a product, I recommend considering the manufacturer’s reputation and whether consistent supply can be maintained, as switching between generic versions occasionally causes variations in control.
9. Frequently Asked Questions (FAQ) about Calan
What is the recommended course of Calan to achieve results for hypertension?
Most patients notice blood pressure reduction within 1-2 weeks, but full effects may take 4 weeks, especially with extended-release formulations. Continuous therapy is necessary for maintained benefit.
Can Calan be combined with beta-blockers?
Concomitant use requires extreme caution due to synergistic effects on AV conduction and contractility. This combination should generally be avoided outside monitored settings.
Is Calan safe during pregnancy?
Verapamil is classified as Category C, meaning risk cannot be ruled out. It may be used when benefits outweigh risks, particularly for arrhythmia management unresponsive to other agents.
How long does Calan stay in your system?
The elimination half-life ranges from 2-7 hours for immediate-release and 12 hours for extended-release, but norverapamil accumulation with chronic dosing extends the pharmacologic effect beyond these timeframes.
10. Conclusion: Validity of Calan Use in Clinical Practice
After four decades of clinical use, Calan maintains an important position in our cardiovascular armamentarium. The risk-benefit profile favors its use in appropriately selected patients, particularly those with hypertension accompanied by supraventricular arrhythmias or angina. The drug’s dual mechanism provides unique advantages that newer agents haven’t rendered obsolete. While constipation remains the most bothersome side effect for many patients, this is typically manageable with dietary modification or mild laxatives.
What continues to surprise me is discovering new applications for this old drug. Just last month, I treated a 72-year-old man with hypertrophic cardiomyopathy and outflow tract obstruction who couldn’t tolerate beta-blockers due to profound fatigue. We initiated low-dose Calan with careful monitoring, and within three weeks, his exertional symptoms improved dramatically without the side effects that had limited previous therapies. His wife remarked that he was gardening again for the first time in years—a simple pleasure that reminded me why we continue to reach for well-understood tools like Calan even as flashier alternatives emerge. The longitudinal follow-up on many of my Calan patients shows sustained benefit over years, with some maintaining the same dose for over a decade without tachyphylaxis or loss of efficacy. That kind of reliability is rare in medicine, and it’s why I keep returning to this trusted agent despite the constant influx of newer options.